| 2.27 0 (0%) | 05-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.78 | 1-year : | 3.1 |
| Resists | First : | 2.38 | Second : | 2.65 |
| Pivot price | 2.32  |
|||
| Supports | First : | 1.95 | Second : | 1.62 |
| MAs | MA(5) : | 2.25  |
MA(20) : | 2.33 |
| MA(100) : | 2.36 |
MA(250) : | 3.88 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.5 |
D(3) : | 43.7 |
| RSI | RSI(14): 47.5 | |||
| 52-week | High : | 7.25 | Low : | 1.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLRN ] has closed above bottom band by 41.3%. Bollinger Bands are 21.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.27 - 2.28 | 2.28 - 2.29 |
| Low: | 2.24 - 2.26 | 2.26 - 2.27 |
| Close: | 2.25 - 2.27 | 2.27 - 2.29 |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Wed, 21 May 2025
ACELYRIN Completes Merger and Delists from Nasdaq - TipRanks
Tue, 13 May 2025
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
Fri, 28 Mar 2025
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Tue, 18 Mar 2025
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now - Yahoo Finance
Fri, 07 Mar 2025
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Yahoo Finance
Fri, 21 Feb 2025
ACELYRIN shares surge on buyout interest By Investing.com - Investing.com Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 101 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 91.9 (%) |
| Shares Short | 3,570 (K) |
| Shares Short P.Month | 3,650 (K) |
| EPS | -2.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -51.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -286 (M) |
| Levered Free Cash Flow | -174 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|